Metabolic medicines

Ephedrine

A sympathomimetic medicine; the history of ephedra weight-loss products does not establish a safe supplement use.

Specific medical indication; historical combination weight trial

Ephedrine molecular structure — Structure reference · C10H15NO

Practical use

Reviewed practical notes

Identify every ingredient: A combination trial cannot assign its benefit or harm to a single component.
Distinguish the product type: A clinical injectable medicine and an herbal supplement are not interchangeable.
Consider interactions: Adrenergic effects can interact with other medicines; a supplement label does not remove that issue.

2002 randomized combination trial

AKOVAZ prescribing information

FDA ingredient and regulatory directory

Overview

Ephedrine stimulates adrenergic signaling and releases norepinephrine. The cited US prescription label covers clinically important low blood pressure during anesthesia. That monitored medical role is different from taking a stimulant product for fat loss.

Risks and limitations

The prescription label identifies rapid heart rate and clinically important medicine interactions. In the historical supplement trial, heart rate, dry mouth and insomnia increased. Failure to observe rare catastrophic events in a modest trial cannot exclude them.

How to read this

FDA banned dietary supplements containing ephedrine alkaloids in 2004 because of unreasonable risk. That US supplement action should not be misstated as a ban on every legitimate ephedrine medicine in every setting.

Research explained

Historical ephedra-plus-caffeine trial

Who was studied

167 adults randomized to an herbal combination or placebo for six months.

What was found

The combination produced greater weight reduction but also increased heart rate and some symptoms, including insomnia.

What it cannot establish

This tested ephedra alkaloids together with caffeine, not isolated ephedrine. The sample and duration cannot settle rare-event safety, and the study predates the FDA supplement ban.

Read the original study

The indication is part of the evidence

AKOVAZ is an ephedrine sulfate injection labeled for anesthesia-related hypotension and administration by trained health professionals. Its approval does not validate an oral weight-loss product or a self-directed stimulant combination.

Supporting source

A supplement ban and a prescription indication can coexist

FDA’s ephedrine-alkaloid action addresses dietary supplements. Always retain the product type and jurisdiction when describing a substance’s regulatory status.

Supporting source